Trial Outcomes & Findings for Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy (NCT NCT02503332)
NCT ID: NCT02503332
Last Updated: 2020-10-06
Results Overview
The square root GA lesion size (i.e. transformed area of GA) was measured by FAF photographs. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
246 participants
Primary outcome timeframe
Baseline (screening) and Month 12.
Results posted on
2020-10-06
Participant Flow
This Phase II, randomized, single-masked, sham injection-controlled study in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) was conducted at 47 sites (46 active) in 3 countries between 24 September 2015 and 14 July 2017 (Data cut-off date, Month 12).
Subjects were randomized in a 2:2:1:1 manner to receive treatment with pegcetacoplan monthly, pegcetacoplan every-other-month (EOM), sham monthly or sham EOM, respectively. A total of 246 subjects were randomized in the study.
Participant milestones
| Measure |
Pegcetacoplan Monthly
Subjects received intravitreal (IVT) injections of pegcetacoplan 15 milligrams (mg)/100 microliters (μL) once monthly for 12 months.
|
Pegcetacoplan EOM
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.
|
Sham Monthly
Subjects received sham injections once monthly for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.
|
Sham EOM
Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
86
|
79
|
41
|
40
|
|
Overall Study
COMPLETED
|
52
|
60
|
33
|
36
|
|
Overall Study
NOT COMPLETED
|
34
|
19
|
8
|
4
|
Reasons for withdrawal
| Measure |
Pegcetacoplan Monthly
Subjects received intravitreal (IVT) injections of pegcetacoplan 15 milligrams (mg)/100 microliters (μL) once monthly for 12 months.
|
Pegcetacoplan EOM
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.
|
Sham Monthly
Subjects received sham injections once monthly for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.
|
Sham EOM
Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.
|
|---|---|---|---|---|
|
Overall Study
Adverse Event
|
17
|
5
|
3
|
1
|
|
Overall Study
Investigator's Decision
|
5
|
1
|
0
|
0
|
|
Overall Study
Sponsor's Decision
|
1
|
0
|
0
|
1
|
|
Overall Study
Subject Request
|
6
|
5
|
2
|
1
|
|
Overall Study
Death
|
0
|
2
|
2
|
0
|
|
Overall Study
Other
|
5
|
6
|
1
|
1
|
Baseline Characteristics
Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy
Baseline characteristics by cohort
| Measure |
Pegcetacoplan Monthly
n=86 Participants
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.
|
Pegcetacoplan EOM
n=79 Participants
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.
|
Sham Pooled
n=81 Participants
Sham Monthly: Subjects received sham injections once monthly for 12 months.
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.
|
Total
n=246 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
79.6 years
STANDARD_DEVIATION 7.51 • n=5 Participants
|
81.0 years
STANDARD_DEVIATION 7.55 • n=7 Participants
|
78.4 years
STANDARD_DEVIATION 7.43 • n=5 Participants
|
79.7 years
STANDARD_DEVIATION 7.54 • n=4 Participants
|
|
Sex: Female, Male
Female
|
55 Participants
n=5 Participants
|
50 Participants
n=7 Participants
|
49 Participants
n=5 Participants
|
154 Participants
n=4 Participants
|
|
Sex: Female, Male
Male
|
31 Participants
n=5 Participants
|
29 Participants
n=7 Participants
|
32 Participants
n=5 Participants
|
92 Participants
n=4 Participants
|
|
Race/Ethnicity, Customized
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race/Ethnicity, Customized
Asian
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
|
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race/Ethnicity, Customized
White
|
84 Participants
n=5 Participants
|
76 Participants
n=7 Participants
|
81 Participants
n=5 Participants
|
241 Participants
n=4 Participants
|
|
Race/Ethnicity, Customized
Other
|
0 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
|
Race/Ethnicity, Customized
Hispanic or Latino
|
2 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
|
Race/Ethnicity, Customized
Not Hispanic or Latino
|
81 Participants
n=5 Participants
|
76 Participants
n=7 Participants
|
77 Participants
n=5 Participants
|
234 Participants
n=4 Participants
|
|
Race/Ethnicity, Customized
Not Reported
|
2 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
|
Race/Ethnicity, Customized
Unknown
|
1 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
|
Region of Enrollment
Australia
|
12 Participants
n=5 Participants
|
11 Participants
n=7 Participants
|
12 Participants
n=5 Participants
|
35 Participants
n=4 Participants
|
|
Region of Enrollment
New Zealand
|
3 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
10 Participants
n=4 Participants
|
|
Region of Enrollment
United States
|
71 Participants
n=5 Participants
|
65 Participants
n=7 Participants
|
65 Participants
n=5 Participants
|
201 Participants
n=4 Participants
|
|
GA Lesion Size (fundus autofluorescence [FAF]) in the Study Eye
|
8.0 millimeter square (mm^2)
STANDARD_DEVIATION 3.84 • n=5 Participants
|
8.9 millimeter square (mm^2)
STANDARD_DEVIATION 4.47 • n=7 Participants
|
8.2 millimeter square (mm^2)
STANDARD_DEVIATION 4.05 • n=5 Participants
|
8.4 millimeter square (mm^2)
STANDARD_DEVIATION 4.12 • n=4 Participants
|
PRIMARY outcome
Timeframe: Baseline (screening) and Month 12.Population: The modified ITT (mITT) population included all randomized subjects who received at least one injection of study drug and had at least one visit at or after Month 2 where primary efficacy data was collected. Subjects were included in their randomized treatment group even if they received the wrong study drug.
The square root GA lesion size (i.e. transformed area of GA) was measured by FAF photographs. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
Outcome measures
| Measure |
Pegcetacoplan Monthly
n=84 Participants
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.
|
Pegcetacoplan EOM
n=78 Participants
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.
|
Sham Pooled
n=80 Participants
Sham Monthly: Subjects received sham injections once monthly for 12 months.
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.
|
|---|---|---|---|
|
Least Square (LS) Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 12
|
0.26 mm
Standard Error 0.025
|
0.28 mm
Standard Error 0.026
|
0.35 mm
Standard Error 0.025
|
PRIMARY outcome
Timeframe: From the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).Population: The safety population included all randomized subjects who received at least one injection of study drug.
A TEAE was defined as any adverse event (AE) that commenced or worsened on or after time of first study drug administration up to 60 days beyond last dose of study drug. A treatment-related TEAE was defined as a TEAE with a relationship to study drug of possibly related or probably related or not reported. Severity of TEAEs were categorized as mild; moderate; severe; life-threatening or death related to TEAE, according to Common Terminology Criteria for AEs v4.03. A TEAE of special interest (TEAESI) was defined as a TEAE of scientific and medical concern specific to pegcetacoplan, whether serious or non-serious.
Outcome measures
| Measure |
Pegcetacoplan Monthly
n=86 Participants
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.
|
Pegcetacoplan EOM
n=79 Participants
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.
|
Sham Pooled
n=81 Participants
Sham Monthly: Subjects received sham injections once monthly for 12 months.
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.
|
|---|---|---|---|
|
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by Severity
Treatment-related TEAEs
|
21 Participants
|
11 Participants
|
0 Participants
|
|
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by Severity
TEAEs
|
65 Participants
|
47 Participants
|
42 Participants
|
|
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by Severity
Serious TEAEs
|
4 Participants
|
2 Participants
|
1 Participants
|
|
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by Severity
TEAEs with mild intensity
|
36 Participants
|
30 Participants
|
28 Participants
|
|
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by Severity
TEAEs with moderate intensity
|
23 Participants
|
14 Participants
|
11 Participants
|
|
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by Severity
TEAEs with severe intensity
|
6 Participants
|
3 Participants
|
3 Participants
|
|
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by Severity
TEAEs with life-threatening intensity
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by Severity
Death related to TEAEs
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by Severity
TEAESIs
|
5 Participants
|
4 Participants
|
0 Participants
|
|
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by Severity
TEAEs leading to study/treatment discontinuation
|
19 Participants
|
5 Participants
|
3 Participants
|
SECONDARY outcome
Timeframe: Baseline (Day 1) and Month 12.Population: The mITT population included all randomized subjects who received at least one injection of study drug and had at least one visit at or after Month 2 where primary efficacy data was collected. Subjects were included in their randomized treatment group even if they received the wrong study drug.
The untransformed area of GA was measured by FAF. Baseline is defined as the last available, non-missing observation prior to first study drug administration.
Outcome measures
| Measure |
Pegcetacoplan Monthly
n=84 Participants
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.
|
Pegcetacoplan EOM
n=78 Participants
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.
|
Sham Pooled
n=80 Participants
Sham Monthly: Subjects received sham injections once monthly for 12 months.
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.
|
|---|---|---|---|
|
LS Mean Change From Baseline in Untransformed GA Lesion Size in the Study Eye at Month 12
|
1.49 mm^2
Standard Error 0.161
|
1.69 mm^2
Standard Error 0.168
|
2.12 mm^2
Standard Error 0.161
|
SECONDARY outcome
Timeframe: Baseline (Day 1) and Month 12.Population: The mITT population included all randomized subjects who received at least one injection of study drug and had at least one visit at or after Month 2 where primary efficacy data was collected. Subjects were included in their randomized treatment group even if they received the wrong study drug.
The BCVA letter score was determined using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. The score ranges from 0 to 100 letters, lower number indicating reduced visual acuity; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.
Outcome measures
| Measure |
Pegcetacoplan Monthly
n=84 Participants
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.
|
Pegcetacoplan EOM
n=78 Participants
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.
|
Sham Pooled
n=80 Participants
Sham Monthly: Subjects received sham injections once monthly for 12 months.
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.
|
|---|---|---|---|
|
LS Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score of the Study Eye at Month 12
|
-3.31 ETDRS letter score
Standard Error 1.352
|
-5.78 ETDRS letter score
Standard Error 1.398
|
-4.36 ETDRS letter score
Standard Error 1.364
|
SECONDARY outcome
Timeframe: Baseline (Day 1) and Month 12.Population: The mITT population included all randomized subjects who received at least one injection of study drug and had at least one visit at or after Month 2 where primary efficacy data was collected. Subjects were included in their randomized treatment group even if they received the wrong study drug.
The LL-BCVA was measured by placing a 2.0-log-unit neutral density filter over the best correction and having the participant read the normally illuminated ETDRS chart. The score ranges from 0 to 100 letters, lower number indicating worse vision; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.
Outcome measures
| Measure |
Pegcetacoplan Monthly
n=84 Participants
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.
|
Pegcetacoplan EOM
n=78 Participants
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.
|
Sham Pooled
n=80 Participants
Sham Monthly: Subjects received sham injections once monthly for 12 months.
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.
|
|---|---|---|---|
|
LS Mean Change From Baseline in Low Luminance BCVA (LL-BCVA) Score in the Study Eye at Month 12
|
-2.73 ETDRS letter score
Standard Error 1.145
|
-3.21 ETDRS letter score
Standard Error 1.184
|
-0.55 ETDRS letter score
Standard Error 1.150
|
SECONDARY outcome
Timeframe: Baseline (Day 1) and Month 12.Population: The mITT population included all randomized subjects who received at least one injection of study drug and had at least one visit at or after Month 2 where primary efficacy data was collected. Subjects were included in their randomized treatment group even if they received the wrong study drug.
The LL-VA deficit score is calculated as BCVA score minus LL-BCVA score. The LL-VA deficit score ranges from 0 to 100 letters, lower number indicating worse deficit.
Outcome measures
| Measure |
Pegcetacoplan Monthly
n=84 Participants
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.
|
Pegcetacoplan EOM
n=78 Participants
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.
|
Sham Pooled
n=80 Participants
Sham Monthly: Subjects received sham injections once monthly for 12 months.
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.
|
|---|---|---|---|
|
LS Mean Change From Baseline in Low Luminance VA (LL-VA) Deficit Score in the Study Eye at Month 12
|
-0.76 ETDRS letter score
Standard Error 1.382
|
-2.40 ETDRS letter score
Standard Error 1.424
|
-3.72 ETDRS letter score
Standard Error 1.385
|
SECONDARY outcome
Timeframe: Baseline (Day 1) and Month 12.Population: The mITT population included all randomized subjects who received at least one injection of study drug and had at least one visit at or after Month 2 where primary efficacy data was collected. Subjects were included in their randomized treatment group even if they received the wrong study drug.
The foveal encroachment in the study eye was measured by FAF. Baseline is defined as the last available, non-missing observation prior to first study drug administration.
Outcome measures
| Measure |
Pegcetacoplan Monthly
n=84 Participants
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.
|
Pegcetacoplan EOM
n=78 Participants
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.
|
Sham Pooled
n=80 Participants
Sham Monthly: Subjects received sham injections once monthly for 12 months.
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.
|
|---|---|---|---|
|
LS Mean Change From Baseline in Distance of GA Lesion From the Fovea (Foveal Encroachment) in the Study Eye at Month 12
|
-0.04 mm
Standard Error 0.011
|
-0.04 mm
Standard Error 0.012
|
-0.06 mm
Standard Error 0.011
|
SECONDARY outcome
Timeframe: From the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).Population: The safety population included all randomized subjects who received at least one injection of study drug.
The number of subjects with any MNV TEAEs in the study eye was identified via clinical review of all ocular TEAEs.
Outcome measures
| Measure |
Pegcetacoplan Monthly
n=86 Participants
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.
|
Pegcetacoplan EOM
n=79 Participants
Subjects received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.
|
Sham Pooled
n=81 Participants
Sham Monthly: Subjects received sham injections once monthly for 12 months.
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.
|
|---|---|---|---|
|
Number of Subjects With Any Macular Neovascularization (MNV) TEAEs in the Study Eye
|
14 Participants
|
5 Participants
|
1 Participants
|
Adverse Events
Pegcetacoplan Monthly: Ocular Study Eye
Serious events: 4 serious events
Other events: 51 other events
Deaths: 0 deaths
Pegcetacoplan EOM: Ocular Study Eye
Serious events: 2 serious events
Other events: 35 other events
Deaths: 0 deaths
Sham Pooled: Ocular Study Eye
Serious events: 1 serious events
Other events: 25 other events
Deaths: 0 deaths
Pegcetacoplan Monthly: Ocular Fellow Eye
Serious events: 0 serious events
Other events: 12 other events
Deaths: 0 deaths
Pegcetacoplan EOM: Ocular Fellow Eye
Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths
Sham Pooled: Ocular Fellow Eye
Serious events: 1 serious events
Other events: 10 other events
Deaths: 0 deaths
Pegcetacoplan Monthly: Non-ocular
Serious events: 12 serious events
Other events: 23 other events
Deaths: 0 deaths
Pegcetacoplan EOM: Non-ocular
Serious events: 23 serious events
Other events: 18 other events
Deaths: 2 deaths
Sham Pooled: Non-ocular
Serious events: 16 serious events
Other events: 23 other events
Deaths: 2 deaths
Serious adverse events
| Measure |
Pegcetacoplan Monthly: Ocular Study Eye
n=86 participants at risk
Ocular TEAEs are summarized for the study eye for all subjects who received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.
|
Pegcetacoplan EOM: Ocular Study Eye
n=79 participants at risk
Ocular TEAEs are summarized for the study eye for all subjects who received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.
|
Sham Pooled: Ocular Study Eye
n=81 participants at risk
Ocular TEAEs are summarized for the study eye for all subjects who randomized to sham monthly and sham EOM treatment groups.
Sham Monthly: Subjects received sham injections once monthly for 12 months.
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.
|
Pegcetacoplan Monthly: Ocular Fellow Eye
n=86 participants at risk
Ocular TEAEs are summarized for the fellow eye for all subjects who received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.
|
Pegcetacoplan EOM: Ocular Fellow Eye
n=79 participants at risk
Ocular TEAEs are summarized for the fellow eye for all subjects who received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.
|
Sham Pooled: Ocular Fellow Eye
n=81 participants at risk
Ocular TEAEs are summarized for the fellow eye for all subjects who randomized to sham monthly and sham EOM treatment groups.
Sham Monthly: Subjects received sham injections once monthly for 12 months.
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.
|
Pegcetacoplan Monthly: Non-ocular
n=86 participants at risk
Non-ocular (systemic) TEAEs are summarized for all subjects who received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.
|
Pegcetacoplan EOM: Non-ocular
n=79 participants at risk
Non-ocular (systemic) TEAEs are summarized for all subjects who received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.
|
Sham Pooled: Non-ocular
n=81 participants at risk
Non-ocular (systemic) TEAEs are summarized for all subjects who randomized to sham monthly and sham EOM treatment groups.
Sham Monthly: Subjects received sham injections once monthly for 12 months.
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.
|
|---|---|---|---|---|---|---|---|---|---|
|
Cardiac disorders
Coronary artery disease
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Cardiac disorders
Mitral valve calcification
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Cardiac disorders
Coronary artery occlusion
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Cardiac disorders
Coronary artery stenosis
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Infections and infestations
Endophthalmitis
|
2.3%
2/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Investigations
Intraocular pressure increased
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Eye disorders
Retinal detachment
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Eye disorders
Dry age-related macular degeneration
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Cardiac disorders
Acute myocardial infarction
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Cardiac disorders
Angina unstable
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
2.3%
2/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
2.5%
2/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Cardiac disorders
Cardiac failure acute
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Cardiac disorders
Cardiac failure congestive
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
4.7%
4/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Cardiac disorders
Sinus node dysfunction
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Cardiac disorders
Supraventricular tachyarrhythmia
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Gastrointestinal disorders
Gastritis
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Gastrointestinal disorders
Inguinal hernia
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Gastrointestinal disorders
Oesophageal obstruction
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Gastrointestinal disorders
Peptic ulcer
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Gastrointestinal disorders
Upper gastrointestinal haemorrhage
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
General disorders
Adverse drug reaction
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
General disorders
Chest pain
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
General disorders
Multiple organ dysfunction syndrome
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
2.5%
2/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Infections and infestations
Appendicitis perforated
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Infections and infestations
Cystitis
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Infections and infestations
Diverticulitis
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Infections and infestations
Escherichia sepsis
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Infections and infestations
Lung abscess
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
2.3%
2/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
2.5%
2/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Infections and infestations
Pneumonia staphylococcal
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Infections and infestations
Post procedural sepsis
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Infections and infestations
Postoperative wound infection
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Injury, poisoning and procedural complications
Ankle fracture
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Injury, poisoning and procedural complications
Cervical vertebral fracture
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Injury, poisoning and procedural complications
Epidural haemorrhage
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Injury, poisoning and procedural complications
Facial bones fracture
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
3.7%
3/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Injury, poisoning and procedural complications
Femur fracture
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Injury, poisoning and procedural complications
Post procedural haemorrhage
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Injury, poisoning and procedural complications
Radius fracture
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Injury, poisoning and procedural complications
Skull fracture
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Injury, poisoning and procedural complications
Spinal fracture
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Injury, poisoning and procedural complications
Subarachnoid haemorrhage
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Injury, poisoning and procedural complications
Subdural haemorrhage
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Metabolism and nutrition disorders
Hypovolaemia
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Musculoskeletal and connective tissue disorders
Spinal column stenosis
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain neoplasm
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive ductal breast carcinoma
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Nervous system disorders
Metabolic encephalopathy
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Nervous system disorders
Spinal claudication
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Nervous system disorders
Syncope
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Nervous system disorders
Transient ischaemic attack
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Nervous system disorders
Trigeminal neuralgia
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Product Issues
Device extrusion
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Psychiatric disorders
Mental status changes
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Renal and urinary disorders
Bladder outlet obstruction
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Renal and urinary disorders
Bladder prolapse
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Reproductive system and breast disorders
Vaginal prolapse
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchiectasis
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonia aspiration
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Vascular disorders
Aortic stenosis
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Vascular disorders
Hypertension
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Vascular disorders
Orthostatic hypotension
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
Other adverse events
| Measure |
Pegcetacoplan Monthly: Ocular Study Eye
n=86 participants at risk
Ocular TEAEs are summarized for the study eye for all subjects who received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.
|
Pegcetacoplan EOM: Ocular Study Eye
n=79 participants at risk
Ocular TEAEs are summarized for the study eye for all subjects who received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.
|
Sham Pooled: Ocular Study Eye
n=81 participants at risk
Ocular TEAEs are summarized for the study eye for all subjects who randomized to sham monthly and sham EOM treatment groups.
Sham Monthly: Subjects received sham injections once monthly for 12 months.
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.
|
Pegcetacoplan Monthly: Ocular Fellow Eye
n=86 participants at risk
Ocular TEAEs are summarized for the fellow eye for all subjects who received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.
|
Pegcetacoplan EOM: Ocular Fellow Eye
n=79 participants at risk
Ocular TEAEs are summarized for the fellow eye for all subjects who received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.
|
Sham Pooled: Ocular Fellow Eye
n=81 participants at risk
Ocular TEAEs are summarized for the fellow eye for all subjects who randomized to sham monthly and sham EOM treatment groups.
Sham Monthly: Subjects received sham injections once monthly for 12 months.
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.
|
Pegcetacoplan Monthly: Non-ocular
n=86 participants at risk
Non-ocular (systemic) TEAEs are summarized for all subjects who received IVT injections of pegcetacoplan 15 mg/100 μL once monthly for 12 months.
|
Pegcetacoplan EOM: Non-ocular
n=79 participants at risk
Non-ocular (systemic) TEAEs are summarized for all subjects who received IVT injections of pegcetacoplan 15 mg/100 μL EOM for 12 months.
|
Sham Pooled: Non-ocular
n=81 participants at risk
Non-ocular (systemic) TEAEs are summarized for all subjects who randomized to sham monthly and sham EOM treatment groups.
Sham Monthly: Subjects received sham injections once monthly for 12 months.
Sham EOM: Subjects received sham injections EOM for 12 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.
|
|---|---|---|---|---|---|---|---|---|---|
|
Eye disorders
Conjunctival haemorrhage
|
18.6%
16/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
11.4%
9/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
9.9%
8/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
2.3%
2/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Eye disorders
Vitreous floaters
|
22.1%
19/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
8.9%
7/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
4.7%
4/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
2.5%
2/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Eye disorders
Eye pain
|
14.0%
12/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
3.8%
3/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
7.4%
6/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Eye disorders
Neovascular age-related macular degeneration
|
11.6%
10/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
6.3%
5/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
2.3%
2/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Eye disorders
Visual impairment
|
4.7%
4/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
11.4%
9/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
3.7%
3/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
3.5%
3/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
5.1%
4/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
2.5%
2/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Eye disorders
Visual acuity reduced
|
2.3%
2/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
5.1%
4/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
2.5%
2/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Eye disorders
Vitreous detachment
|
5.8%
5/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
2.5%
2/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
3.7%
3/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
2.3%
2/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
2.5%
2/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Eye disorders
Dry eye
|
3.5%
3/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
6.2%
5/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
2.3%
2/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
4.9%
4/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Investigations
Intraocular pressure increased
|
8.1%
7/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
10.1%
8/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.2%
1/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
5.8%
5/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
1.3%
1/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
3.7%
3/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
2.3%
2/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
6.2%
5/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
10.5%
9/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
11.4%
9/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
8.6%
7/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Infections and infestations
Viral upper respiratory tract infection
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
2.3%
2/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
3.8%
3/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
9.9%
8/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
8.1%
7/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
2.5%
2/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
2.5%
2/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
|
Vascular disorders
Hypertension
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
0.00%
0/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
4.7%
4/86 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
7.6%
6/79 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
7.4%
6/81 • TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
The safety population included all randomized subjects who received at least one injection of study drug. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.
|
Additional Information
Apellis Clinical Trial Information Line
Apellis Pharmaceuticals, Inc
Phone: 1-833-284-6361
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place